Physician profile
David Brian Dellinger
NPI 1093785404
$3,566.12
in general payments reported to CMS, 2019-2025
12 companies · $39.83 in 2025
The $39.83 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $587 · 2020: $2,446 · 2021: $42.91 · 2022: $103 · 2023: $174 · 2024: $174 · 2025: $39.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $387.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,137.42 | 2020 | |
| Organogenesis INC. | $476.09 | 2019-2023 | Puraply |
| Kerecis Limited | $371.58 | 2020-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Kci USA, INC. | $146.25 | 2019-2021 | |
| Indivior INC. | $122.08 | 2020 | |
| Smith+Nephew, INC. | $79.92 | 2019-2024 | Regranex, Collagenase Santyl |
| Paratek Pharmaceuticals, INC. | $74.75 | 2020 | |
| Misonix INC | $61.04 | 2019 | |
| Polynovo North America LLC | $39.83 | 2025 | Novosorb Btm |
| Solventum Corporation | $28.73 | 2024 | Activ.A.C. |
| Tactile Systems Technology INC | $14.32 | 2019 | |
| Eyevance Pharmaceuticals LLC | $14.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dellinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.